Page last updated: 2024-08-23

mifepristone and Peritoneal Carcinomatosis

mifepristone has been researched along with Peritoneal Carcinomatosis in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, H; Chen, J; Jia, L; Li, T; Liu, J; Liu, W; Wang, J; Zheng, N	1
Brady, WE; Hoffman, JS; Mannel, RS; Rocereto, TF; Rotmensch, J; Shahin, MS; Small, L	1
Copel, L; Halevy, A; Halpern, Z; Samuk, I; Sandbank, J; Ziv, Y	1

Trials

1 trial(s) available for mifepristone and Peritoneal Carcinomatosis

Article	Year
A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecologic oncology, 2010, Volume: 116, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Mifepristone; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms	2010

Article

Year

A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study.

Gynecologic oncology, 2010, Volume: 116, Issue:3

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Mifepristone; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms

2010

Other Studies

2 other study(ies) available for mifepristone and Peritoneal Carcinomatosis

Article	Year
Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention. Molecular carcinogenesis, 2017, Volume: 56, Issue:8 Topics: Abortifacient Agents; Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Chemoprevention; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Mifepristone; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Peritoneal Neoplasms; Peritoneum; Receptors, CXCR4; Signal Transduction	2017
Mifepristone (RU486), a pure antiprogesterone drug, in combination with vinblastine for the treatment of progesterone receptor-positive desmoid tumor. Techniques in coloproctology, 2010, Volume: 14, Issue:3 Topics: Adenomatous Polyposis Coli; Adult; Anastomosis, Surgical; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Fibromatosis, Aggressive; Humans; Imaging, Three-Dimensional; Male; Mifepristone; Peritoneal Neoplasms; Proctocolectomy, Restorative; Receptors, Progesterone; Tomography, X-Ray Computed; Vinblastine	2010

Article

Year

Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.

Molecular carcinogenesis, 2017, Volume: 56, Issue:8

Topics: Abortifacient Agents; Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Chemoprevention; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Mifepristone; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Peritoneal Neoplasms; Peritoneum; Receptors, CXCR4; Signal Transduction

2017

Mifepristone (RU486), a pure antiprogesterone drug, in combination with vinblastine for the treatment of progesterone receptor-positive desmoid tumor.

Techniques in coloproctology, 2010, Volume: 14, Issue:3

Topics: Adenomatous Polyposis Coli; Adult; Anastomosis, Surgical; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Fibromatosis, Aggressive; Humans; Imaging, Three-Dimensional; Male; Mifepristone; Peritoneal Neoplasms; Proctocolectomy, Restorative; Receptors, Progesterone; Tomography, X-Ray Computed; Vinblastine

2010